The group has over 20 years of experience in clinical and translational research on Alzheimer’s disease. The main scientific interest is the use of neuroimaging techniques and other biomarkers in persons with or at risk for cognitive impairment. Acquisitions and innovations in fundamental neurosciences, ICT, and technology are uptaken and translated for use into a clinical setting for better pathophysiological understanding, diagnosis, prognosis, disease tracking, drug therapy, and rehabilitation. Specific topics of investigation are: the clinical use of imaging and fluid biomarkers; in vivo neurobiology of Alzheimer’s disease; the clinical use of innovative PET ligands; harmonisation of imaging markers for clinical use; development of innovative image analysis environments based on advanced ICT technology.
Analysis of Psychological Symptoms Following Disclosure of Amyloid-Positron Emission Tomography Imaging Results to Adults With Subjective Cognitive Decline.
Disclosure of Genetic Risk Factors for Alzheimer's Disease to Cognitively Healthy Individuals-From Current Practice towards a Personalised Medicine Scenario.
Low-dose brain irradiation normalizes TSPO and CLUSTERIN levels and promotes the non-amyloidogenic pathway in pre-symptomatic TgF344-AD rats.
Predicting AT(N) pathologies in Alzheimer's disease from blood-based proteomic data using neural networks.
Département de psychiatrie